Arca Biopharma (ABIO) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Arca Biopharma (NASDAQ:ABIO) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.12, Fidelity Earnings reports.

ABIO remained flat at $$15.10 on Thursday. 1,373,640 shares of the company traded hands, compared to its average volume of 505,415. Arca Biopharma has a 52 week low of $4.68 and a 52 week high of $23.04.

Separately, ValuEngine downgraded shares of Arca Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.

ILLEGAL ACTIVITY WARNING: “Arca Biopharma (ABIO) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at

Arca Biopharma Company Profile

ARCA biopharma, Inc is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).

See Also: How is a buy-side analyst different from a sell-side analyst?

Earnings History for Arca Biopharma (NASDAQ:ABIO)

Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with's FREE daily email newsletter.